Phospholipogenic Pharmaceuticals Are Associated with a Higher Incidence of Histological Findings than Nonphospholipogenic Pharmaceuticals in Preclinical Toxicology Studies

<table>Percent nonphospholipogenic and phospholipogenic compound administrations yielding non-PLD histological findings, by organ. For every organ, on average, phospholipogenic administration resulted in more non-PLD histological findings than did negative compound administration. The data represent that pooled from three species and all study durations.</table>

Journal of Toxicology

fig6

Figure 6

Figure 6: Phospholipogenic Pharmaceuticals Are Associated with a Higher Incidence of Histological Findings than Nonphospholipogenic Pharmaceuticals in Preclinical Toxicology Studies 

Figure 6 | Phospholipogenic Pharmaceuticals Are Associated with a Higher Incidence of Histological Findings than Nonphospholipogenic Pharmaceuticals in Preclinical Toxicology Studies 